ArticleCureus2026
A Non-randomized Clinical Trial on the Effectiveness and Complications of Two Different Streptokinase Dosages in Elderly Patients With ST-Elevation Myocardial Infarction (STEMI).
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStreptokinase is widely used for thrombolysis in acute myocardial infarction (AMI), but concerns about complications have led to its underutilization in elderly patients. This study aimed to compare the efficacy and safety of standard-dose, i.e., 15 lakh international units (IU), versus half-dose (7.5 lakh IU) streptokinase in elderly patients with ST-elevation myocardial infarction (STEMI). MATERIALS AND
methodsThis prospective, observational study included 103 patients with STEMI aged over 70 years, admitted within 12 hours of symptom onset. Patients were divided into two groups receiving either 15 lakh IU (n = 59) or 7.5 lakh IU (n = 44) of streptokinase. Efficacy was assessed by ST-segment resolution ≥ 50% after 90 minutes. Complications and mortality were monitored in both groups.
resultsBaseline demographic and clinical characteristics were comparable between the groups. Improvement in left ventricular ejection fraction (LVEF) from admission to one month was similar (2.75% vs. 2.84%, p = 0.885), and rates of reperfusion success (78.0% vs. 77.3%) and ST-segment resolution ≥ 50% (61.0% vs. 59.1%) did not differ significantly. Complications were more frequent in the 7.5 lakh IU group, particularly major bleeding (11.4% vs. 3.4%), though differences were not statistically significant. In-hospital mortality was low and comparable between the two groups (5.1% vs. 6.8%, p = 0.690).
conclusionHalf-dose streptokinase demonstrated comparable efficacy to the standard dose in achieving myocardial reperfusion in elderly patients having STEMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.